Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides

Chinese Medical Journal

Volumn 114, Issue 9, 2001, Pages 929-932

  Pan, Lingya ^a   Tong, Ying ^a   Jin, Ying ^a   Zhou, Sheng ^b   Zhang, Yi ^b   Yang, Xiuyu ^a   Mao, Ning ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Antsense; Gene, mdr1; Multiple drug resistance; Neoplasma; Oligodeoxynucleotides; Ovarian

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA ACTIN; DOXORUBICIN; GLYCOPROTEIN P; LIPOFECTAMINE; MESSENGER RNA; PACLITAXEL; RHODAMINE 123;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE GENE 1; OVARY CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034807988     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin in patients with stage II and IV ovarian cancer. New Engl J Med 1996; 334: 1-6.
2. Anil KS, Richard EB. Drug resistance in ovarian cancer: from the lab to the clinic. Obstet Gynecol 1998; 92: 312-319.
3. Matthew WR, Mack NB, Claudine R, et al. Gene therapy for ovarian carcinoma. Semin Oncol 1998; 25: 397-406.
4. Gottesman M. How cancer evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1993; 53: 747-754.
5. Gottesman M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
6. Thigpen JT. The role of chemotherapy in gynecologic cancer. In: Rubin SC, ed. Chemotherapy of gynecologic cancer. New York: Lippincott-Raven; 1996.
7. Swenerton K, Muss HB, Robinson EG. Salvage chemotherapy for refractory disease. In: Gershenson DM, McGuire WP, eds. Ovarian cancer controversies in management. New York: Churchill Livingstone; 1998: 169-194.
8. Ludescher C, Thaler J, Drach D, et al. Detection of P-glycoprotein in human tumor samples using rhodamine 123. Br J Haematol 1992; 82: 161-168.
9. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth and cell kill. J Immunol Methods 1989: 119-203.
10. Sayuri M, Toshido M, Minoko T, et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998; 91: 3163-3171.
11. Alan MG, Deborah LS, Mariusz ZR. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-736.